Target Discovery and Validation Reviews and Protocols

112 Sørlie
31. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire,
W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification
of the HER-2/neu oncogene. Science 235, 177–182.
32. Ahr, A., Karn, T., Solbach, C., et al. (2002) Identification of high risk breast-cancer
patients by gene expression profiling. Lancet 359, 131–132.
33. Huang, E., Cheng, S. H., Dressman, H., et al. (2003) Gene expression predictors
of breast cancer outcomes. Lancet 361, 1590–1596.
34. Ma, X. J., Wang, Z., Ryan, P. D., et al. (2004) A two-gene expression ratio predicts
clinical outcome in breast cancer patients treated with tamoxifen. Cancer
Cell 5, 607–616.
35. van de Vijver, M. J., He, Y. D., van’t Veer, L. J., et al. (2002) A gene-expression signature
as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999–2009.
36. Onda, M., Emi, M., Nagai, H., et al. (2004) Gene expression patterns as marker
for 5–year postoperative prognosis of primary breast cancers. J. Cancer Res. Clin.
Oncol. 130, 537–545.
37. Nagahata, T., Onda, M., Emi, M., et al. (2004) Expression profiling to predict
postoperative prognosis for estrogen receptor-negative breast cancers by analysis
of 25, 344 genes on a cDNA microarray. Cancer Sci. 95, 218–225.
38. Eden, P., Ritz, C., Rose, C., Ferno, M., and Peterson, C. (2004) “Good Old” clinical
markers have similar power in breast cancer prognosis as microarray gene
expression profilers. Eur. J. Cancer 40, 1837–1841.
39. Sasco, A. J. (2003) Breast cancer and the environment. Horm. Res. 60 Suppl 3, 50.
40. Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early
breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’
Collaborative Group. Lancet 351, 1451–1467.
41. Citron, M. L., Berry, D. A., Cirrincione, C., et al. (2003) Randomized trial of
dose-dense versus conventionally scheduled and sequential versus concurrent
combination chemotherapy as postoperative adjuvant treatment of node-positive
primary breast cancer: first report of Intergroup Trial C9741/Cancer and
Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431–1439.
42. Ayers, M., Symmans, W. F., Stec, J., et al. (2004) Gene Expression Profiles
Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and
Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast
Cancer. J. Clin. Oncol. 22, 2284–2293.
43. Chang, J. C., Wooten, E. C., Tsimelzon, A., et al. (2003) Gene expression profiling
for the prediction of therapeutic response to docetaxel in patients with breast cancer.
Lancet 362, 362–369.
44. Iwao-Koizumi, K., Matoba, R., Ueno, N., et al. (2005) Prediction of docetaxel
response in human breast cancer by gene expression profiling. J. Clin. Oncol. 23,
422–431.
45. Jansen, M. P., Foekens, J. A., van Staveren, I. L., et al. (2005) Molecular classification
of tamoxifen-resistant breast carcinomas by gene expression profiling.
J. Clin. Oncol. 23, 732–740.